TherapeuticsMD (TXMD) investor relations material

Executive summary

• Transitioned to a pharmaceutical royalty company in December 2022, licensing key products and focusing on royalty income from Mayne Pharma and other partners; no longer engaging in R&D or commercial operations.

• All commercial operations are now reflected as discontinued operations; only one full-time employee remains, with external consultants supporting operations.

• Continues to evaluate strategic alternatives, including potential mergers, acquisitions, or asset sales, with no set timetable for completion.

• Reported net income from continuing operations of $164K for Q2 2026, down from $545K in Q2 2025.

• Operating expenses increased to $1.7M, up 2.3% year-over-year, mainly due to higher general and administrative costs and patent write-offs.

Financial highlights

• Q2 2026 license revenue was $869K, down $83K from Q2 2025; six-month revenue rose to $1.59M, up $248K year-over-year.

• Q2 2026 net income was $155K ($0.01/share), down from $551K ($0.05/share) in Q2 2025; six-month net income was $250K, up from a $102K loss in 2025.

• Cash and cash equivalents at June 30, 2026 were $9.2M, up from $7.48M at year-end 2025.

• Operating expenses for Q2 2026 were $1.7M, up 2.3% year-over-year; six-month operating expenses fell 5.7% to $3.13M.

Outlook and guidance

• Ongoing reliance on royalty revenue from Mayne Pharma, Theramex, and Knight; milestone payments possible if sales thresholds are met.

• Management is exploring a range of strategic alternatives but provides no assurance or timeline for any transaction.

• Substantial doubt exists about ability to continue as a going concern for the next 12 months due to unresolved disputes, potential slowdowns in royalty streams, and capital market uncertainty.